Michael J Hassett

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint What does breast cancer treatment cost and what is it worth?
    Michael J Hassett
    Department of Medicine, Harvard Medical School, 250 Longwood Avenue, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 27:829-41, ix. 2013
  2. pmc Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer
    Michael J Hassett
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:2218-26. 2012
  3. pmc Chemotherapy-related hospitalization among community cancer center patients
    Michael J Hassett
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Oncologist 16:378-87. 2011
  4. pmc Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer
    Michael J Hassett
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:5553-60. 2008
  5. pmc Regional variation in spending and survival for older adults with advanced cancer
    Gabriel A Brooks
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Natl Cancer Inst 105:634-42. 2013
  6. pmc Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ
    Nils D Arvold
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 118:6022-30. 2012
  7. pmc Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care
    Jennifer S Haas
    Division of General Medicine and Primary Care, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    Breast Cancer Res Treat 130:619-26. 2011
  8. pmc Selecting high priority quality measures for breast cancer quality improvement
    Michael J Hassett
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Med Care 46:762-70. 2008
  9. pmc Modeling the effectiveness of initial management strategies for ductal carcinoma in situ
    Djøra I Soeteman
    Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    J Natl Cancer Inst 105:774-81. 2013
  10. doi request reprint Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions
    Gregory A Abel
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 119:1065-72. 2013

Collaborators

Detail Information

Publications17

  1. doi request reprint What does breast cancer treatment cost and what is it worth?
    Michael J Hassett
    Department of Medicine, Harvard Medical School, 250 Longwood Avenue, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 27:829-41, ix. 2013
    ..Currently, patients and providers may not consider costs when making most treatment decisions; this is likely to change as payment reform spreads. ..
  2. pmc Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer
    Michael J Hassett
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:2218-26. 2012
    ..One of the first commercially available GEP tests, a 21-gene profile, was developed to estimate the benefit of adjuvant chemotherapy for hormone receptor-positive breast cancer (HR-positive BC)...
  3. pmc Chemotherapy-related hospitalization among community cancer center patients
    Michael J Hassett
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Oncologist 16:378-87. 2011
    ....
  4. pmc Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer
    Michael J Hassett
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:5553-60. 2008
    ....
  5. pmc Regional variation in spending and survival for older adults with advanced cancer
    Gabriel A Brooks
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Natl Cancer Inst 105:634-42. 2013
    ..Medicare spending varies substantially across the United States. We evaluated the association between mean regional spending and survival in advanced cancer...
  6. pmc Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ
    Nils D Arvold
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 118:6022-30. 2012
    ..The authors described the characteristics of SBC and examined associations between the pathologic features of SBC and index DCIS cases...
  7. pmc Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care
    Jennifer S Haas
    Division of General Medicine and Primary Care, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
    Breast Cancer Res Treat 130:619-26. 2011
    ..While GEP testing was associated with an overall decrease in adjuvant chemotherapy, we did not find differences in serious chemotherapy-associated adverse events or charges during the 12 months following diagnosis...
  8. pmc Selecting high priority quality measures for breast cancer quality improvement
    Michael J Hassett
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Med Care 46:762-70. 2008
    ..We sought to develop a simple, explicit strategy for prioritizing breast cancer quality measures based on their potential to highlight areas where quality improvement efforts could most impact a population...
  9. pmc Modeling the effectiveness of initial management strategies for ductal carcinoma in situ
    Djøra I Soeteman
    Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    J Natl Cancer Inst 105:774-81. 2013
    ..We sought to quantify the tradeoffs among alternative management strategies for DCIS with respect to disease outcomes and breast preservation...
  10. doi request reprint Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions
    Gregory A Abel
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 119:1065-72. 2013
    ....
  11. pmc Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer
    Rachel L Yung
    Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Natl Cancer Inst 104:1102-5. 2012
    ..Partnerships between Medicaid programs and cancer registries may help identify at-risk women and facilitate the implementation of quality improvement strategies...
  12. pmc Factors influencing changes in employment among women with newly diagnosed breast cancer
    Michael J Hassett
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:2775-82. 2009
    ..The authors of this report assessed whether chemotherapy or radiation therapy was associated with a disruption in employment during the year after a breast cancer diagnosis...
  13. pmc Behavioral health services for women who have breast cancer
    Vanessa Azzone
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 27:706-12. 2009
    ....
  14. ncbi request reprint Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer
    Michael J Hassett
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, 454 STE 21, Boston, MA 02115 6084, USA
    J Natl Cancer Inst 98:1108-17. 2006
    ..The number, nature, and costs of serious adverse effects experienced by younger women receiving chemotherapy for breast cancer outside of clinical trials are unknown...
  15. ncbi request reprint Genomic testing and therapies for breast cancer in clinical practice
    Jennifer S Haas
    Division of General Medicine and Primary Care, Boston, MA 02120, USA
    Am J Manag Care 17:e174-81. 2011
    ....
  16. pmc Use of annual mammography among older women with ductal carcinoma in situ
    Phyllis Brawarsky
    Division of General Medicine and Primary Care, Department of Medicine, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120 1613, USA
    J Gen Intern Med 27:500-5. 2012
    ..As ductal carcinoma in situ (DCIS) is a risk factor for invasive breast cancer, ongoing annual mammography is important for cancer control, yet little is known about racial/ethnic and other disparities in use among older women with DCIS...
  17. pmc Impact of neoadjuvant chemotherapy on breast reconstruction
    Yue Yung Hu
    Center for Surgery and Public Health, Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer 117:2833-41. 2011
    ..Multiple studies have confirmed the safety of both chemotherapy before breast surgery and immediate reconstruction. Little has been written about the effect of neoadjuvant chemotherapy on decisions about reconstruction...